Forty Seven secures first half of planned $75M Series A
February 25, 2016
Forty Seven, a clinical-stage immuno-oncology company, has completed the first half of a committed $75 million Series A financing. Lightspeed Venture Partners and Sutter Hill Ventures led the round, with participation from Clarus Ventures and GV. The company, which aims to engage new and complementary phagocytic pathways that enhance anti-tumor efficacy and selectivity, has also licensed the rights to multiple immuno-oncology programs from Stanford University.